[144] Fulgent Genetics, Inc. SEC Filing

Rhea-AI Filing Summary

Fulgent Genetics, Inc. (FLGT) filed a Form 144 notice reporting a proposed sale of 1,128 shares of common stock through Morgan Stanley Smith Barney on 09/03/2025, with an aggregate market value of $24,846.15. The filer acquired the shares as restricted stock vesting on 02/28/2022 as equity compensation (32,000 shares acquired on that date). The filing shows prior sales by the same person in August 2025 totaling 1,895 shares for gross proceeds of $40,725.28. Total shares outstanding are reported as 30,609,044.

Positive

• Compliant disclosure: The filer provided required Rule 144 details including broker, acquisition date, and nature of acquisition.
• Transparency on recent activity: Prior August 2025 sales (696 and 1,199 shares) and gross proceeds are reported.

Negative

• Insider selling: The person for whose account the securities are to be sold has recently sold shares in August 2025, indicating ongoing disposition of vested equity.

Insights

Securities Analyst

TL;DR Insider plans to sell a small block of vested restricted shares; recent discrete August sales are disclosed.

The Form 144 documents a proposed brokered sale of 1,128 shares worth $24,846.15 and discloses prior August 2025 sales of 696 and 1,199 shares. The shares were acquired via restricted stock vesting on 02/28/2022 (32,000 shares originally). Relative to the issuer's reported 30,609,044 outstanding shares, the proposed sale and recent August disposals are immaterial in size but are appropriately disclosed under Rule 144. No financial performance data or forward-looking statements are included.

Corporate Governance Expert

TL;DR Filing meets Rule 144 disclosure requirements; shows insider liquidity from vested equity.

The notice provides required information: acquisition date and nature (restricted stock vest), broker details, sale timing, and recent dispositions by the same person. Signature and representation language regarding material nonpublic information are included. The filing does not indicate any unusual governance actions or regulatory issues; it documents routine insider selling activity tied to equity compensation vesting.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC 1 New York Plaza, 38th FL New York NY 10004	1128	24846.15	30609044	09/03/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	02/28/2022	Resticted stock vest	Fulgent Genetics, Inc.			32000	02/28/2022	Equity compensation for services rendered

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Jian Xie C/O Fulgent Genetics, Inc. 4399 Santa Anita Avenue El Monte CA 91731	Common Stock	08/25/2025	696	14965.08
Jian Xie C/O Fulgent Genetics, Inc. 4399 Santa Anita Avenue El Monte CA 91731	Common Stock	08/27/2025	1199	25760.2

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for Fulgent Genetics (FLGT) report?

The Form 144 reports a proposed brokered sale of 1,128 common shares on 09/03/2025 with aggregate market value $24,846.15.

How were the shares being sold acquired according to the filing?

The shares were acquired as restricted stock that vested on 02/28/2022 as equity compensation from Fulgent Genetics, Inc.

What recent sales by the same person are disclosed in the Form 144?

The filing discloses sales on 08/25/2025 (696 shares, $14,965.08) and 08/27/2025 (1,199 shares, $25,760.20).

Who is the broker handling the proposed sale?

The broker named is Morgan Stanley Smith Barney LLC located at 1 New York Plaza, 38th FL, New York, NY 10004.

How many shares outstanding does the filing report for FLGT?

The filing reports 30,609,044 shares outstanding.